Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Provencio, M; Serna-Blasco, R; Nadal, E; Insa, A; García-Campelo, MR; Rubio, JC; Dómine, M; Majem, M; Rodríguez-Abreu, D; Martínez-Martí, A; Carpeño, JD; Cobo, M; Vivanco, GL; Del Barco, E; Caro, RB; Viñolas, N; Aranda, IB; Viteri, S; Pereira, E; Royuela, A; Calvo, V; Martín-López, J; García-García, F; Casarrubios, M; Franco, F; Sánchez-Herrero, E; Massuti, B; Cruz-Bermúdez, A; Romero, A – 2022 – 10.1200/JCO.21.02660